NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- AXIM Biotechnologies (OTC:AXIM) is setting the "green standard" in the industrial hemp industry, tapping two world-renown experts to advise on the Company's pharmaceutical pipeline and cannabinoid-based drug delivery platforms.
Two main indications are currently under clinical investigation: pain and spasticity among Multiple Sclerosis patients and a novel drug delivery system for Inflammatory Bowel Disease (IBD)/Irritable Bowel Syndrome (IBS) and Crohn's disease. To advance research and product development, the Company proudly announces the expansion of its advisory board with the addition of two top experts: Prof. John Zajicek and Prof. Renger Witkamp.
"Here at AXIM Biotechnologies, we expect to be on the forefront of development of innovative pharmaceutical solutions for diseases that currently have no efficient remedies," states George. E. Anastassov, MD, DDS, MBA and Chief Executive Officer for AXIM Biotechnologies. "We are currently focused on pain and spasticity as well as Inflammatory Bowel Disease, Irritable Bowel Syndrome and Crohn's disease. AXIM Biotechnologies is delighted to report that two of the world's leaders in these respective fields, Prof. John Zajicek and Prof. Renger Witkamp, have joined our advisory board, bringing with them a wealth of knowledge and invaluable experience for advancing our efforts."
Photos accompanying this release are available at
Professor John Zajicek brings extensive neurological knowledge with regard to Multiple Sclerosis and will advise AXIM Biotechnologies on protocols for clinical studies. Prof. Zajicek is currently Vice Dean Research and Chair of Clinical Neuroscience with the Plymouth University Peninsula Colleges of Medicine and Dentistry, and Honorary Consultant at Derriford Hospital in Plymouth. He is also Chair of the UK NIHR Nervous System Disorders Speciality Group, Board Member of the MRC Neuroscience and Mental Health Board, Co-Director of an NHS research network and Director of the Peninsula Clinical Trials Unit.
Prof. Renger Witkamp, an expert on inflammation mechanisms and drug delivery platforms, will provide insight for investigative solutions for Inflammatory Bowel Disease/Irritable Bowel Syndrome as well as Crohn's disease. Dr. Witkamp's research is predominantly directed at further elucidating the actions of plant cannabinoids and endocannabinoids on inflammatory processes and eating behavior. Practical applications of this program include muscle preservation during chronic disease and intestinal disorders.
According to the National Multiple Sclerosis website, there are 2.3 million globally diagnosed with Multiple Sclerosis. However, since the CDC does not require U.S. physicians to report new cases, and because symptoms can be completely invisible, the prevalence of MS in the U.S. "can only be estimated." Crohn's disease reportedly affects 1 in 10,000 reported in the U.K., while IBS in the U.S. alone is reported to account for an estimated $1.7-10 billion in direct medical costs, with an additional $20 billion in indirect costs, for a total of $21.7-30 billion. IBS symptoms reported among global population range from 6% in Canada to as much as 34% in Pakistan, 43% in Brazil and 46% in Mexico.
Dr. Anastassov concludes, "AXIM Biotechnologies appreciates the dedication that Professors Zajicek and Witkamp made in their respective bodies of research. Both are extremely valuable in advancing cannabinoid-based sciences and we are thrilled to have them as part of AXIM Biotechnologies' advisory board."
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@AXIMBiotechnologies.com or call 858-380-5478.
About AXIM Biotechnologies:
AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
The photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.
CONTACT: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
Source:AXIM Biotechnologies, Inc